Haihe Biopharma Co., Ltd is a global, values-based, R&D driven biopharmaceutical leader headquartered in China with operation centers in the US and Japan, and mainly focuses on innovative anti-tumor therapies. The company has the fully capability of drug discovery, development, manufacture and commercialization and delivers life-saving therapies to cancer patients in China, even the world widely. As an R&D focused company led by an academician of the Chinese Academy of Engineering, Haihe Biopharma is committed in-house innovator with global perspective management and R&D team. Currently Haihe Biopharma has one approved product (Gumarontinib, Haiyitan® ) in China and 9+ drug candidates.
Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide.
Haihe Biopharma’s Gumarontinib has been approved by NMPA
NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Gumarontinib
The NDA for Haihe Biopharma’s Gumarontinib has been accepted for review by the CDE.
Haihe established its Japan office
Haihe completed worth
1.2 billion yuan Series B Funding
Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.
Haihe established its US office
Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan
Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer
Haihe completed Haihe completed $136.6 million Series A Funding
Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical
Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.